BI is presently securing $2 million in seed capital for its commercialization program. This financing round is expected to close on 1.11.2017, after which the BI action plan will be initiated. Interested investors should contact Dr. Sigalit Carmel, Founder and CEO at: sigalit@bioimmunate.com; mobile 972-54-720-2228.